Literature DB >> 19507195

Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation.

Ting Li1, Vincent Kam Wai Wong, Xiao Qin Yi, Yuen Fan Wong, Hua Zhou, Liang Liu.   

Abstract

Pseudolaric acid B (PAB) is a major bioactive component of the medicinal plant Pseudolarix kaempferi. Traditional medicine practitioners in Asia have been using the roots of this plant to treat inflammatory and microbial skin diseases for centuries. In the current study, in vitro immunosuppressive effect of PAB and the underlying mechanisms have been investigated. The results showed that PAB dose-dependently suppressed human T lymphocyte proliferation, IL-2 production and CD25 expression induced by co-stimulation of PMA plus ionomycin or of anti-OKT-3 plus anti-CD28. Mechanistic studies showed that PAB significantly inhibited nuclear translocation of NF-kappaB p65 and phosphorylation and degradation of IkappaB-alpha evoked by co-stimulation of PMA plus ionomycin. PAB could also suppress the phosphorylation of p38 in the MAPKs pathway. Based on these evidences, we conclude that PAB suppressed T lymphocyte activation through inhibition of NF-kappaB and p38 signaling pathways; this would make PAB a strong candidate for further study as an anti-inflammatory agent. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19507195     DOI: 10.1002/jcb.22230

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model.

Authors:  Bing Yu; Mei-Hong Li; Wei Wang; Ying-Qing Wang; Yi Jiang; Sheng-Ping Yang; Jian-Min Yue; Jian Ding; Ze-Hong Miao
Journal:  J Mol Med (Berl)       Date:  2012-03-10       Impact factor: 4.599

Review 2.  Drug discovery enters a new era with multi-target intervention strategy.

Authors:  Xiao-ying Tian; Liang Liu
Journal:  Chin J Integr Med       Date:  2012-04-11       Impact factor: 1.978

3.  Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells.

Authors:  Li Hou; Bo Xu; Wei Guo; Fu-Xiang Ran; Jing-Tao Liu; Xia Yuan; Hong-Zheng Fu; Jing-Rong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

4.  Pseudolaric acid B attenuates atopic dermatitis-like skin lesions by inhibiting interleukin-17-induced inflammation.

Authors:  Zhen Yang; Meilun Liu; Wei Wang; Yiteng Wang; Bo Cao; Ying Gao; Hong Chen; Tan Li
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

Review 5.  A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B.

Authors:  Mei-Lun Liu; Dan Sun; Tan Li; Hong Chen
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

6.  Pseudolaric Acid B Attenuates High Salt Intake-Induced Hypertensive Left Ventricular Remodeling by Modulating Monocyte/Macrophage Phenotypes.

Authors:  Fang-Fang Yu; Guo-Hong Yang; Shao-Bo Chen; Xiu-Long Niu; Wei Cai; Yan-Yan Tao; Xiu-Juan Wang; Ming Li; Yu-Ming Li; Ji-Hong Zhao
Journal:  Med Sci Monit       Date:  2021-09-08

Review 7.  Target identification of anticancer natural products using a chemical proteomics approach.

Authors:  Swadhapriya Bhukta; Pushparathinam Gopinath; Rambabu Dandela
Journal:  RSC Adv       Date:  2021-08-18       Impact factor: 4.036

8.  Shikonin Suppresses Human T Lymphocyte Activation through Inhibition of IKK β Activity and JNK Phosphorylation.

Authors:  Ting Li; Fenggen Yan; Rui Wang; Hua Zhou; Liang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

Review 9.  Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches.

Authors:  Mi Hee Park; Jin Tae Hong
Journal:  Cells       Date:  2016-03-29       Impact factor: 6.600

10.  Isoliquiritigenin suppresses human T Lymphocyte activation via covalently binding cysteine 46 of IκB kinase.

Authors:  Fenggen Yan; Fen Yang; Rui Wang; Xiao Jun Yao; Liping Bai; Xing Zeng; JiaJun Huang; Vincent Kam Wai Wong; Christopher Wai Kei Lam; Hua Zhou; Xiaohui Su; Juan Liu; Ting Li; Liang Liu
Journal:  Oncotarget       Date:  2017-05-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.